What Does Wall Street Think About Neurocrine Biosciences (NBIX)?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $149 from $144 while keeping an Outperform rating on the shares.

The firm told investors in a research note that, according to its latest analysis of prescription trends, Crenessity’s strong launch is expected to continue, with the drug exceeding Q3 consensus estimates.

It added that shares look to have appreciated closer to fair value, which may point towards increasing near-term optimism.

The same day, Sean Laaman from Morgan Stanley also expressed bullish sentiments for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), giving the stock a Buy rating with a $163 price target.

Currently, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has an analyst consensus of Strong Buy, with the stock’s median price target of $141.87 implying an upside of 19.83% from current levels.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company with a focus on neuroscience. It is involved in the research and development, sale, and commercialization of pharmaceuticals that treat neuroendocrine, neurological, and neuropsychiatric disorders.

The company’s product portfolio includes treatments for chorea associated with Huntington’s disease, tardive dyskinesia, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.